Your Article Summary
See Latest ArticlesWeekly and twice-weekly bortezomib in patients with systemic AL-amyloidosis: results of a phase 1 dose-escalation study
Blood, 06/08/09
Reece DE et al. - Once-weekly and twice-weekly bortezomib appear generally well tolerated in relapsed AL, with promising hematologic responses.
Related Articles
Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma
Blood, 11/02/09
Relevance Score: 89%
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Annals of Oncology, 10/30/09
Relevance Score: 89%
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology, 10/02/09
Relevance Score: 89%
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology, 10/01/09
Relevance Score: 89%
VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: Cohort analysis of the phase III Vista study
Journal of Clinical Oncology, 10/29/09
Relevance Score: 87%
Today in Amyloidosis...keeping you current
Receive free subspecialty "5-minute updates" via email
Clinical features and functional significance of the P369S/ R408Q variant in pyrin, the familial Mediterranean fever protein
Annals of Rheumatic Diseases, 12/11/09
MEFV mutations in Egyptian patients suffering from familial Mediterranean fever: analysis of 12 gene mutations
Rheumatology International, 10/16/09
Classification of amyloidosis by laser microdissection and mass spectrometry based proteomic analysis in clinical biopsy specimens
Blood, 10/09/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
First-line DMARD choice in early rheumatoid arthritis - Do prognostic factors play a role?
Rheumatology, 12/15/09
Use of oral bisphosphonates and risk of venous thromboembolism: A population-based case-control study
Osteoporosis International, 12/15/09
Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-&alpha blocker therapy
Rheumatology, 12/15/09